There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > EMMPRIN


EMMPRIN Molecule Information

Target Synonym:Extracellular matrix metalloproteinase inducer;CD_antigen=CD147;TCSF;EMMPRIN;BSG;Leukocyte activation antigen M6;5F7;Tumor cell-derived collagenase stimulatory factor;OK blood group antigen;Collagenase stimulatory factor;Basigin
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

EMMPRIN Protein Product ListCompare or Buy

EMMPRIN Part of Bioactivity data

Human EMMPRIN, His Tag (Cat. No. ) MALS images

The purity of Human EMMPRIN, His Tag(Cat. No. CD7-H5222) was more than 95% and the molecular weight of this protein is around 20-30 kDa verified by SEC-MALS.

EMMPRIN Molecule Synonym Name


EMMPRIN Molecule Background

CD147, also known as Basigin (BSG), or extracellular matrix metalloproteinase inducer (EMMPRIN). The human basigin protein contains 269 amino acids that form two heavily glycosylated C2 type immunoglobulin-like domains at the N-terminal extracellular portion. A second form of basigin has also been characterized that contains one additional immunoglobulin-like domain in its extracellular portion. As members of the immunoglobulin superfamily play fundamental roles in intercellular recognition involved in various immunologic phenomena, differentiation, and development, basigin is thought also to play a role in intercellular recognition and regulate several distinct functions, such as spermatogenesis, expression of the monocarboxylate transporter and the responsiveness of lymphocytes. Basigin is a type I integral membrane receptor that has many ligands, including the cyclophilin (CyP) proteins Cyp-A and CyP-B and certain integrins.

EMMPRIN References

EMMPRIN Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Iodine[131I] Metuximab Approved Huasun Biological Iodine[131I] Metuximab Injection cfda Hepatocellular carcinoma (HCC) 2016-05-17 Hepatocellular carcinoma (HCC) Details

EMMPRIN Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Gavilimomab CBL-1 Phase Ⅲ Abgenix, Genzyme Psoriasis, Graft versus host disease, Rheumatoid arthritis (RA), Rejection of renal transplantation Details
Meplazumab HI6H8 Phase Ⅱ Pacific Meinuoke Biopharmaceutical, The Fourth Military Medical University Malaria, Coronavirus Disease 2019 (COVID-19) Details
Mertuzumab Phase Ⅰ Pacific Meinuoke Biopharmaceutical, The Fourth Military Medical University Non small cell lung cancer (NSCLC) Details
Anti-CD147 CAR T cell therapy (Xijing Hospital) Phase Ⅰ Xijing Hospital Glioblastoma Details

This web search service is supported by Google Inc.